

Posting Date: June 26, 2020

Closing Date: July 7, 2020 11:30 a.m. ET

Reference Number: 20-034580

To: NCI Bid Board

From: Sharon Coles-Calloway  
NCI DCEG Purchasing Agent  
[coless@mail.nih.gov](mailto:coless@mail.nih.gov)

Subject: NCI Bid Board Posting – 244k Oligonucleotide Library

The National Cancer Institute Division of Cancer Epidemiology and Genetics Laboratory of Translational Genomics (LTG) conducts focused studies to explain the functional significance of particular regions of the genome conclusively identified in cancer-specific genome-wide association studies (GWAS) and linkage studies in high-risk families. The overall goal of the lab is to develop new approaches to the study of the genetic basis of cancer and its outcomes. Specifically, we are investigating the genetic basis of strong association signals identified in candidate gene association studies, loci identified by linkage analysis of high-risk families, or genome-wide association studies.

The 244K oligonucleotide library will be used to generate constructs for massively parallel reporter assays (MPRA) in pancreatic cells at Laboratory of Translational Genomics (LTG)/DCEG/NCI. The overall goal of our laboratory is to develop new approaches to the study of the genetic basis of cancer and its outcomes. Specifically, LTG are investigating the genetic basis of strong association signals identified in candidate gene association studies, loci identified by linkage analyses in high risk families, or genome wide association studies (GWAS).

The National Cancer Institute plans to purchase access to the Pancreatic Cancer GWAS MPRA 244K oligonucleotide Library from Agilent Technologies Inc. Wilmington, DE. This is not a request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine is the party can fully meet this requirement. The capability statement must be received in the contracting office by 11:30 AM on July 7, 2020 ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

The 244K oligonucleotide library will be used to generate constructs for the massively parallel reporter assay (MPRA), in order to understand functional and biological mechanism underlying pancreatic GWAS loci. Performing the MPRA assay will prioritize the most plausible functional candidate variants / genes from the identified pancreatic cancer GWAS loci. The 244K pancreatic cancer cell DNA oligonucleotide library has unique characteristics and performance due to the following specifics :

1. The Library is a high complexity library, containing 244,000 DNA oligonucleotides
2. The Library is long oligonucleotides 191 to 210 nucleotides.
3. The Library offers high quality oligos through OLID design.

Agilent Technologies is the only provider of pancreatic cancer cell MPRA 244K oligonucleotide Library. Our lab has previously used an oligonucleotide Library generated by Agilent Technoliges, and has established the best conditions and parameters to perform the MPRA assay in our pancreatic cell lines. Using oligonucleotide library from a different company would require additional optimization and validation that would be costly and time consuming. By using the Agilent Technologies library we will also be provided with technical support in trouble shooting from experienced experts at Agilent Biotechnologies. To our knowledge other vendors such as Integrated DNA Technologies do not provide the quality of service meeting our criteria including length and fidelity of oligo synthesis as well as the library complexity.

Attached Documents:

SF18

Statement of Work

FAR Clause 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment.

FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (AUG 2019) is applicable and available in full text upon request

<b>REQUEST FOR QUOTATION (THIS IS NOT AN ORDER)</b>	THIS RFQ <input checked="" type="checkbox"/> IS <input type="checkbox"/> IS NOT A SMALL BUSINESS SET-ASIDE	PAGE 1 OF 1 PAGES 1
---	--	---------------------

1. REQUEST NO.	2. DATE ISSUED 06/26/2020	3. REQUISITION/PURCHASE REQUEST NO. 20-034580	4. CERT. FOR NAT. DEF. UNDER BDSA REG. 2 AND/OR DMS REG. 1
----------------	------------------------------	--	--

5a. ISSUED BY NIH/NCI-CCR P-ARC	6. DELIVER BY (Date) 30 days from receipt of order
------------------------------------	---

5b. FOR INFORMATION CALL (NO COLLECT CALLS)	7. DELIVERY <input checked="" type="checkbox"/> FOB DESTINATION <input type="checkbox"/> OTHER (See Schedule)
---	--

NAME Sharon Coles-Calloway, Purchasing Agent	TELEPHONE NUMBER AREA CODE: 240 NUMBER: 276-7348	9. DESTINATION a. NAME OF CONSIGNEE
---	---	--

8. TO: a. NAME	b. COMPANY	b. STREET ADDRESS
-------------------	------------	-------------------

c. STREET ADDRESS	c. CITY
-------------------	---------

d.. CITY	e.. STATE	f.. ZIP CODE	d.. STATE	e. ZIP CODE
----------	-----------	--------------	-----------	-------------

10. PLEASE FURNISH QUOTATIONS TO THE ISSUING OFFICE IN BLOCK 5a ON OR BEFORE CLOSE OF BUSINESS (Date) 7/7/2020 11:30 ET	<b>IMPORTANT:</b> This is a request for information, and quotations furnished are not offers. If you are unable to quote, please indicate on this form and return it to the address in Block 5a. This request does not commit the Government to pay any costs incurred in the preparation of the submission of this quotation or to contract for supplies or services. Supplies are of domestic origin unless otherwise indicated by quoter. Any representations and/or certifications attached to this Request for Quotations must be completed by the quoter.
--	---

**11. SCHEDULE (Include applicable Federal, State and local taxes)**

ITEM NO. (a)	SUPPLIES/SERVICES (b)	QUANTITY (c)	UNIT (d)	UNIT PRICE (e)	AMOUNT (f)
001	244K Oligonucleotide Library  Notice of Intent: If submitting a capability statement, please e-mail only 1 copy of the technical capability statement to Sharon Coles-Calloway at coless@mail.nih.gov  See attached statement of need.  This will be awarded as a Firm-Fixed Price Contract.	1	ea	\$ _____	\$ _____

12. DISCOUNT FOR PROMPT PAYMENT	a. 10 CALENDAR DAYS (%)	b. 20 CALENDAR DAYS (%)	c. 30 CALENDAR DAYS (%)	d. CALENDAR DAYS NUMBER   PERCENTAGE
---------------------------------	-------------------------	-------------------------	-------------------------	---

NOTE: Additional provisions and representations are  are  are not attached.

13. NAME AND ADDRESS OF QUOTER	14. SIGNATURE OF PERSON AUTHORIZED TO SIGN QUOTATION	15. DATE OF QUOTATION
--------------------------------	--	-----------------------

a. NAME OF QUOTER	16. SIGNER	
-------------------	------------	--

b. STREET ADDRESS	a. NAME (Type or print)	b. TELEPHONE AREA CODE
-------------------	-------------------------	---------------------------

c. COUNTY	e. STATE	f. ZIP CODE	c. TITLE (Type or print)	NUMBER
-----------	----------	-------------	--------------------------	--------

## **STATEMENT OF NEED (SON)**

### **1.0 TITLE**

Purchase a 244K high complexity DNA Oligonucleotide Library to be used to generate constructs for the Massively Parallel Reporter Assay (MPRA).

### **2.0 BACKGROUND**

National Institutes of Health  
National Cancer Institute  
Division of Cancer Epidemiology and Genetics  
Laboratory of Translational Genomics

The overall goal of our laboratory is to develop new approaches to the study of the genetic basis of cancer and its outcomes. Specifically, LTG are investigating the genetic basis of strong association signals identified in candidate gene association studies, loci identified by linkage analyses in high risk families, or genome wide association studies (GWAS). GWAS has identified 20 pancreatic cancer susceptibility loci. The DNA oligonucleotide library we plan to purchase consists of sequences that are noncoding variants of interest in pancreatic cancer.

Functional understanding of the biological mechanisms underlying these GWAS loci has not been conclusively identified for most of these loci. To this end, incorporating functional annotation data could potentially improve the prediction, and direct testing of allelic function for multiple individual variants could be a valuable resource. To address these issues and quickly prioritize the most plausible functional candidate variants from the most recently identified pancreatic cancer GWAS loci, we propose to adopt the Massively Parallel Reporter Assay (MPRA). The 244K DNA oligonucleotide library will be used to generate constructs for the Massively Parallel Reporter Assay (MPRA).

### **3.0 TYPE OF ORDER**

This is a Firm Fixed Price Purchase Order.

### **4.0 SPECIAL ORDER REQUIREMENTS**

The contractor will provide a DNA oligonucleotide library.

### **4.1 PRODUCT FEATURES/SALIENT CHARACTERISTICS**

The 244K high complexity DNA Oligonucleotide Library will be used to generate constructs for the Massively Parallel Reporter Assay (MPRA).

## STATEMENT OF NEED (SON)

The following product features / characteristics are required for this requirement:

- 1 Library of 244,000 DNA Oligonucleotides
- 191 to 210 nucleotides in length
- OLID 1 : 0000000

### 4.2 DELIVERY / INSTALLATION

The contractor shall deliver the library within 3 weeks from the contract award.

The delivery will be made to:

Irene Collins, Biologist  
Email collinsi@mail.nih.gov  
Phone 1-240-760-6479  
Fax 1-240-541-4442

National Institutes of Health  
National Cancer Institute  
Division of Cancer Epidemiology and Genetics  
Laboratory of Translational Genomics

8717 Grovemont Circle  
Building ATC, Room 127  
Gaithersburg MD 20877

### 4.3 TRAINING

There is no training requirement.

### 5.0 PAYMENT

The contractor shall receive payment after acceptance. Payment authorization requires submission and acceptance of invoice to the NCI COR and to NIH Commercial Accounts, per attached Invoice and Payment Provisions.

Payment shall be made once. Payment authorization requires submission and approval of invoices to the COR and NIH OFM, in accordance with the payment provisions listed below:

## STATEMENT OF NEED (SON)

The following clause is applicable to all Purchase Orders, Task or Delivery Orders, and Blanket Purchase Agreement (BPA) Calls: PROMPT PAYMENT (JUL 2013) FAR 52.232-25. Highlights of this clause and NIH implementation requirements follow:

### I INVOICE REQUIREMENTS

- A. An invoice is the Contractor's bill or written request for payment under the contract for supplies delivered or services performed. A proper invoice is an "Original" which must include the items listed in subdivisions 1 through 12, below, in addition to the requirements of FAR 32.9. If the invoice does not comply with these requirements, the Contractor will be notified of the defect within 7 days after the date the designated billing office received the invoice (3 days for meat, meat food products, or fish, and 5 days for perishable agricultural commodities, dairy products, edible fats or oils) with a statement of the reasons why it is not a proper invoice. (See exceptions under II., below.) Untimely notification will be taken into account in the computation of any interest penalty owed the Contractor.
1. Vendor/Contractor: Name, Address, Point of Contact for the invoice (Name, title, telephone number, e-mail and mailing address of point of contact).
  2. Remit-to address (Name and complete mailing address to send payment).
  3. Remittance name must match exactly with name on original order/contract. If the Remittance name differs from the Legal Business Name, then both names must appear on the invoice.
  4. Invoice date.
  5. Unique invoice #s for all invoices per vendor regardless of site.
  6. NBS document number formats must be included for awards created in the NBS: Contract Number; Purchase Order Number; Task or Delivery Order Number and Source Award Number (e.g., Indefinite Delivery Contract number; General Services Administration number); or, BPA Call Number and BPA Parent Award Number.
  7. Data Universal Numbering System (DUNS) or DUNS + 4 as registered in the Central Contractor Registration (CCR).
  8. Federal Taxpayer Identification Number (TIN). In those exceptional cases where a contractor does not have a DUNS number or TIN, a Vendor Identification Number (VIN) must be referenced on the invoice. The VIN is the number that appears after the contractor's name on the face page of the award document.
  9. Identify that payment is to be made using a three-way match.
  10. Description of supplies/services that match the description on the award, by line billed.\*
  11. Freight or delivery charge must be billed as shown on the award. If it is included in the item price do not bill it separately. If identified in the award as a separate line item, it must be billed separately.
  12. Quantity, Unit of Measure, Unit Price, Extended Price of supplies delivered or services performed, as applicable, and that match the line items specified in the award.\*

## STATEMENT OF NEED (SON)

\* NOTE: If your invoice must differ from the line items on the award, please contact the Contracting Officer before submitting the invoice. A modification to the order or contract may be needed before the invoice can be submitted and paid.

- B. Shipping costs will be reimbursed only if authorized by the Contract/Purchase Order. If authorized, shipping costs must be itemized. Where shipping costs exceed \$100, the invoice must be supported by a bill of lading or a paid carrier's receipt.
- C. Mail an original and 1 copy of the itemized invoice to:

National Institutes of Health  
Office of Financial Management, Commercial Accounts  
2115 East Jefferson Street, Room 4B-432, MSC 8500  
Bethesda, MD 20892-8500

For inquiries regarding payment call: (301) 496-6088

In order to facilitate the prompt payment of invoices, it is recommended that the vendor submit a photocopy of the invoice to the "Consignee" designated for the acquisition in blocks 6A – 6E of the face page of the Order/Award document.

### II. INVOICE PAYMENT

- A. Except as indicated in paragraph B., below, the due date for making invoice payments by the designated payment office shall be the later of the following two events:
  - 1. The 30th day after the designated billing office has received a proper invoice.
  - 2. The 30th day after Government acceptance of supplies delivered or services performed.
- B. The due date for making invoice payments for meat and meat food products, perishable agricultural commodities, dairy products, and edible fats or oils, shall be in accordance with the Prompt Payment Act, as amended.

### III. INTEREST PENALTIES

- A. An interest penalty shall be paid automatically, if payment is not made by the due date and the conditions listed below are met, if applicable.
  - 1. A proper invoice was received by the designated billing office.
  - 2. A receiving report or other Government documentation authorizing payment was processed and there was no disagreement over quantity, quality, or contractor compliance with a term or condition.
  - 3. In the case of a final invoice for any balance of funds due the contractor for supplies delivered or services performed, the amount was not subject to further settlement actions between the Government and the Contractor.

## STATEMENT OF NEED (SON)

- B. Determination of interest and penalties due will be made in accordance with the provisions of the Prompt Payment Act, as amended, the Contract Disputes Act, and regulations issued by the Office of Management and Budget.

### IV. PROVIDING ACCELERATED PAYMENT TO SMALL BUSINESS SUBCONTRACTORS, FAR 52.232-40 (DEC 2013)

- a) Upon receipt of accelerated payments from the Government, the Contractor shall make accelerated payments to its small business subcontractors under this contract, to the maximum extent practicable and prior to when such payment is otherwise required under the applicable contract or subcontract, after receipt of a proper invoice and all other required documentation from the small business subcontractor.
- b) The acceleration of payments under this clause does not provide any new rights under the prompt Payment Act.  
Include the substance of this clause, include this paragraph c, in all subcontracts with small business concerns, including subcontracts with small business concerns for the acquisition of commercial items.

**52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment.**

As prescribed in 4.2105(a), insert the following provision:

REPRESENTATION REGARDING CERTAIN TELECOMMUNICATIONS AND VIDEO SURVEILLANCE SERVICES OR EQUIPMENT (AUG 2019)

(a) Definitions. As used in this provision—

Covered telecommunications equipment or services, Critical technology, and Substantial or essential component have the meanings provided in clause 52.204-25, Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment.

(b) Prohibition. Section 889(a)(1)(A) of the John S. McCain National Defense Authorization Act for Fiscal Year 2019 (Pub. L. 115-232) prohibits the head of an executive agency on or after August 13, 2019, from procuring or obtaining, or extending or renewing a contract to procure or obtain, any equipment, system, or service that uses covered telecommunications equipment or services as a substantial or essential component of any system, or as critical technology as part of any system. Contractors are not prohibited from providing—

(1) A service that connects to the facilities of a third-party, such as backhaul, roaming, or interconnection arrangements; or

(2) Telecommunications equipment that cannot route or redirect user data traffic or permit visibility into any user data or packets that such equipment transmits or otherwise handles.

(c) Representation. The Offeror represents that—

It [ ] will, [ ] will not provide covered telecommunications equipment or services to the Government in the performance of any contract, subcontract or other contractual instrument resulting from this solicitation.

(d) Disclosures. If the Offeror has responded affirmatively to the representation in paragraph (c) of this provision, the Offeror shall provide the following information as part of the offer—

(1) All covered telecommunications equipment and services offered (include brand; model number, such as original equipment manufacturer (OEM) number, manufacturer part number, or wholesaler number; and item description, as applicable);

(2) Explanation of the proposed use of covered telecommunications equipment and services and any factors relevant to determining if such use would be permissible under the prohibition in paragraph (b) of this provision;

(3) For services, the entity providing the covered telecommunications services (include entity name, unique entity identifier, and Commercial and Government Entity (CAGE) code, if known); and

(4) For equipment, the entity that produced the covered telecommunications equipment (include entity name, unique entity identifier, CAGE code, and whether the entity was the OEM or a distributor, if known).

(End of provision)